← Back to Search

Angiogenesis Inhibitor

Antiangiogenic Therapy for Pediatric Brain Cancer (MEMMAT Trial)

Q: What is the current enrollment size of this research endeavor?

Affirmative. According to clinicaltrials.gov, this medical experiment is currently enrolling participants and was initially posted on April 1st 2014 with the latest update being August 24th 2022. The trial aims to recruit a total of 100 patients from 2 distinct sites.

Q: Is there still availability to join this experiment?

Affirmative. The trial details hosted on clinicaltrials.gov demonstrate that this study is actively recruiting and first appeared online April 1st 2014 before being amended August 24th 2022. At present, 100 patients must be sourced from two separate medical sites.

Q: How secure is this remedy for those receiving it?

With only initial safety data available and no evidence of efficacy yet, our team at Power assigned this treatment a score of 2.

Phase 2

Recruiting

Led By Andreas Peyrl, MD

Research Sponsored by Medical University of Vienna

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Female or male, aged from 0 to <20 years at the time of original diagnosis

Relapsed or progressive medulloblastoma, ependymoma or ATRT with at least one site of untreated recurrent disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 years

Awards & highlights

MEMMAT Trial Summary

This trial is testing a new combination of drugs to treat children with medulloblastoma, ependymoma, and ATRT who have relapsed or are progressing. The goal is to improve survival while maintaining quality of life.

Who is the study for?

This trial is for children and young adults up to age 20 with recurrent medulloblastoma, ependymoma or ATRT. They must have confirmed diagnosis at relapse, normal organ/bone marrow function, and a performance status indicating they can engage in most activities. Pregnant individuals, those with known drug hypersensitivity, unhealed fractures or infections are excluded.Check my eligibility

What is being tested?

The study tests biweekly intravenous bevacizumab combined with oral thalidomide, celecoxib, fenofibrate and alternating low-dose etoposide/cyclophosphamide. It also includes alternating courses of intrathecal etoposide/cytarabine aiming to prolong survival while maintaining quality of life in heavily pretreated patients.See study design

What are the potential side effects?

Potential side effects include high blood pressure due to antiangiogenic therapy (bevacizumab), fatigue from chemotherapy drugs (etoposide/cyclophosphamide), skin numbness/tingling from thalidomide, stomach issues from celecoxib/fenofibrate and risk of infection due to bone marrow suppression.

MEMMAT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I was diagnosed before turning 20 years old.

Select...

My cancer has returned or worsened and has not been treated yet.

Select...

My cancer is confirmed as medulloblastoma, ependymoma, or ATRT.

Select...

I can do most activities myself, or my child can play and engage in normal activities.

MEMMAT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Efficacy

Secondary outcome measures

Angiogenic factors

Feasibility

Overall survival rate

+4 more

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Medical University of ViennaLead Sponsor

1,135 Previous Clinical Trials

1,901,559 Total Patients Enrolled

Andreas Peyrl, MDPrincipal Investigator - Medical University of Vienna

Medical University of Vienna

Monika Chocholous, MDStudy ChairMedical University of Vienna

Media Library

Bevacizumab (Angiogenesis Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT01356290 — Phase 2

Medulloblastoma Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT01356290 — Phase 2

Bevacizumab (Angiogenesis Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01356290 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current enrollment size of this research endeavor?

"Affirmative. According to clinicaltrials.gov, this medical experiment is currently enrolling participants and was initially posted on April 1st 2014 with the latest update being August 24th 2022. The trial aims to recruit a total of 100 patients from 2 distinct sites."

Answered by AI

Is there still availability to join this experiment?

"Affirmative. The trial details hosted on clinicaltrials.gov demonstrate that this study is actively recruiting and first appeared online April 1st 2014 before being amended August 24th 2022. At present, 100 patients must be sourced from two separate medical sites."

Answered by AI